Mablink Bioscience
Lyon, France · Founded 2018 · $40.5M raised
- Headquarters
- Lyon
- Employees
- 11–50
- Founded
- 2018
- Business Model
- B2B
- Website
- mablink.com
- Total Funding
- $40.5M
- Last Round
- $35.6M Series AOct 2022
- Rounds
- 2
About
Mablink Bioscience was a French biotechnology company founded in 2018 and based in Lyon, France, developing next-generation antibody-drug conjugates (ADCs) based on its proprietary PSARlink drug-linker technology. The company's platform enabled the creation of highly potent ADCs with improved tolerability and therapeutic windows compared to earlier-generation conjugates, targeting oncology indications. Mablink raised a €31M Series A led by Sofinnova Partners and Mérieux Equity Partners before being acquired by Eli Lilly and Company in late 2023.
Summary
Mablink Bioscience is a Biotech company based in Lyon, France, founded in 2018. It has raised $40.5M in total across 2 rounds, most recently a $35.6M Series A round in Oct 2022. Investors include Sofinnova Partners, Mérieux Equity Partners and Elaia.
Funding History
Sign up to view the funding chart
Create a free account with 25 free credits every month, no card needed, to unlock funding history, valuations, and tech stacks.
Oct 2022
Sign up to see all 2 rounds
Seed through Series A — per-round amounts, valuations, and who invested in each round.
Investors
Similar Companies
China's leading blood products manufacturer
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Biopharmaceutical services company
Specialty pharmaceutical company
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/mablink-bioscience"><img src="https://indexed.vc/api/badge/company/mablink-bioscience" alt="Mablink Bioscience on Indexed.vc" width="260" height="76" /></a>